Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Positive Data from Novovax Ebola Vaccine Trial

    By Global Biodefense StaffJuly 21, 2015
    Ebola Vaccine Development
    Share
    Facebook LinkedIn Reddit Email

    Novavax, Inc. today announced positive top-line data from a Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M as part of the World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine Clinical Trials.

    The trial demonstrated that the Ebola GP Vaccine was highly immunogenic, well-tolerated and, in conjunction with Novavax’ proprietary Matrix-M adjuvant, resulted in significant antigen dose-sparing.

    The Ebola GP Vaccine clinical trial is a randomized, observer-blinded, dose-escalation trial to evaluate the safety and immunogenicity of the vaccine, with and without Matrix-M, in 230 healthy adults between 18 and 49 years of age. Participants received either one or two intramuscular injections ranging from 6.5µg to 50µg of antigen on study days 0 and 21. Immunogenicity was assessed at multiple time points including days 28 and 35.

    The adjuvanted Ebola GP Vaccine was highly immunogenic at all dose levels. The adjuvanted two-dose regimens induced Ebola anti-GP antibody geometric mean responses between 45,000 and 70,000 ELISA units (GMEU), representing a 500 to 750-fold rise over baseline at day 35. The adjuvanted single dose vaccine regimen induced GMEU between 1700 and 3400, representing a 21 to 27-fold rise over baseline at day 35.

    “We are pleased to have the opportunity to share these positive data with the WHO. Novavax’ recombinant nanoparticle technology and proprietary Matrix-M adjuvant differentiates our Ebola GP Vaccine. The Phase 1 clinical data show that our vaccine was well-tolerated and elicited very high Ebola antibody responses,” said Gregory Glenn, M.D., Senior Vice President, Research and Development. “These data, together with two positive challenge studies in non-human primates, suggest that the Ebola GP Vaccine would be protective in humans.”

    “These Ebola GP Vaccine data, in combination with clinical data from our H7N9 VLP vaccine candidate and preclinical data from our vaccine candidate for Middle East Respiratory Syndrome coronavirus, provide additional validation of our nanoparticle vaccine platform,” said Stanley C. Erck, President and CEO. “Further, our recombinant vaccines do not need to be shipped or stored frozen, a key consideration for a vaccine developed against a novel lethal virus with pandemic potential.”

    Ebola Emerging Threats Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDoD Seeks Tuberculosis Disinfectant
    Next Article Industry Day Announced for Joint CBRNE Advanced Capability Sets

    Related Stories

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    The Basics on the Nipah Virus Outbreak in India

    September 19, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.